Introduction
============

Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammation caused by uncontrolled proliferation of activated lymphocytes and histiocytes.[@b1-mjhid-9-1-e2017057] The diagnosis of HLH is challenging in patients with prolonged fever, unresponsive to antibiotics. In 1994 the Histiocyte Society defined a set of diagnostic criteria; they were subsequently revised in 2004. The diagnosis of HLH can be established either by molecular diagnosis consistent with HLH and/or in presence of 5/8 clinical and laboratory criteria for HLH: fever, splenomegaly, cytopenia (affecting ≥2 of 3 lineages in peripheral blood), hypertriglyceridemia and/or hypofibrinogenemia, hemophagocytosis in bone marrow or spleen or lymph nodes, low or absent NK cell activity, ferritin ≥500μg/l, soluble CD25 (soluble IL-2 receptor) ≥2,400 U/ml. Other supportive evidence includes cerebral symptoms with moderate pleocytosis and/or elevated protein, elevated transaminases and bilirubin, LDH. All features of HLH can be explained by high concentrations of inflammatory cytokines and organ infiltration by activated lymphocytes and histiocytes.[@b2-mjhid-9-1-e2017057],[@b3-mjhid-9-1-e2017057]

HLH can be primitive in children, underlying inherited immune deficiencies. Primary HLH is an autosomal recessive or X-linked primary immune deficiency including familial HLH (FLH) in which the clinical syndrome of HLH is the only manifestation. Four subtypes of FLH are defined by mutations in the following genes: PRF1 in FHL2, UNC13D in FHL3, STX11 in FHL4, and STXBP2 in FHL5. The Chediak-Higashi syndrome (CHS 1), Griscelli syndrome (GS 2), Hermansky--Pudlak syndrome (HPS) and X linked proliferative syndrome (XLP) are primary immune deficiencies having distinctive clinical features besides the recurrent primary HLH.[@b2-mjhid-9-1-e2017057]--[@b4-mjhid-9-1-e2017057]

However, HLH is, often, an acquired or secondary syndrome which can occur in all age groups. Infection-associated HLH could be triggered by various agents such as viruses of the herpes group, especially Epstein-Barr virus (EBV) and cytomegalovirus (CMV) or by no viral agents such as Leishmania. Acquired HLH could also be associated with malignant diseases, especially lymphomas and to autoimmune diseases \[[@b2-mjhid-9-1-e2017057]--[@b5-mjhid-9-1-e2017057]\]. It has rarely been described HLH secondary to inborn errors of metabolism such as Lysinuric protein intolerance (LPI), a rare metabolic disorder resulting from recessive-inherited mutations in the SLC7A7 gene encoding the cationic amino-acids transporter subunit y+LAT1. This pathology is characterized by protein-rich food intolerance with secondary urea cycle disorder. It is a multiorgan disease, that could lead to infiltrative lung disease, kidney failure or auto-immune complications. The phenotypic heterogeneity of LPI has resulted in various misdiagnoses.[@b6-mjhid-9-1-e2017057]--[@b11-mjhid-9-1-e2017057]

We report, herein, the case of 9-month-old boy investigated for a persistent HLH with very high hyperferritinemia. Throughout this case, we describe the atypical presentation and outcome of HLH and we insist on differential diagnosis of chronic HLH that must be kept in mind of specialists.

Report of the Case
==================

Case presentation and clinical history
--------------------------------------

M.K is a 9-month-old boy, born from a consanguineous marriage. He had been breastfed for seven months with normal growth. Since food diversification, he exhibited poor weight gain, developed recurrent diarrhea, hepatomegaly, and splenomegaly with pancytopenia, increased serum ferritin and lactate dehydrogenase (LDH) level. Hence, he was referred to the immune-hematologic unit, for hemophagocytic lymphohistiocytosis (HLH) suspicion.

Initial workup
--------------

Physical examination showed pallor, hypotonia, failure to thrive, liver and spleen enlargement. No fever was noted. The physical examination did not reveal other abnormalities. Urine bandlets showed proteinuria and microscopic hematuria. Laboratory findings ([Table 1](#t1-mjhid-9-1-e2017057){ref-type="table"}) showed pancytopenia with normochromic normocytic non-regenerative anemia; neutropenia, lymphopenia, and thrombocytopenia), hyperferritinemia (8000 ng/ml), elevated triglycerides (14 mmol/l), high cholesterol (8 mmol/l) ([Figure 1](#f1-mjhid-9-1-e2017057){ref-type="fig"}), elevated very low-density lipoproteins (VLDL) and low high-density lipoproteins (HDL). He had low fibrinogen (0.74 g/l), without other signs of disseminated intravascular coagulation, increased LDH (3200 UI/l), low urea (1,29 mmol/l) and normal creatinine. Other routine biological tests were normal. Blood and bone marrow smears showed no hemophagocytosis. Cerebrospinal fluid (CSF) exam showed no activated cells. Cerebral MRI was normal.

Differential diagnosis and further investigations
-------------------------------------------------

These clinical features of Hemophagocytic lymphohistiocytosis (HLH) prompted performing other investigations looking for an acquired HLH. So a complete workup was made to rule out an infection, an autoimmune disease or malignancy: microbiological and autoimmunity tests were negative, and blood and bone marrow smears showed no blasts.

Differential diagnosis and further investigations
-------------------------------------------------

A primary HLH was suspected. The patient had no albinism suggesting a GS 2 or a CHS 1. He had no EBV infection suggesting an XLP. FLH was thought to be the primary cause of HLH due to parental consanguinity, history of a cousin with the same signs died at the age of 4 months, in the absence of other evident causes. Nevertheless, perforin expression and degranulation test were regular. Other underlying primary immune deficiency was searched: Immunologic tests showed average immunoglobulin G, A and M levels, moderate global lymphopenia CD4, CD8, B and NK and no increased activated lymphocytes ([Table 2](#t2-mjhid-9-1-e2017057){ref-type="table"}).

Final diagnosis
---------------

Moreover, several atypical elements were noted in this HLH: absence of fever, hypotonia without neurological activation detected on the CSF exam and cerebral MRI, recurrent diarrhea, hematuria and proteinuria, very high cholesterol level, and not increased HLA-DR expression. All these manifestations beginning since food diversification oriented to lysinuric protein intolerance (LPI). In fact, other metabolic errors mimicking HLH similarly like lysosomal acid lipase deficiency, or galactosemia manifest in the first days of life or at lactation, and Gaucher disease was excluded by absence of the typical cells in bone marrow and by a regular glucocerebrosidase activity in cultured fibroblasts.

Serum ammonium level was found increased at 112UI/l (normal ≤70UI/l). Metabolic tests showed an increased urinary excretion of orotic acid. The amino acid analyses from plasma and urine showed low plasma levels of cationic amino acids (CAAs) and increased urinary excretion of CAAs. Organic - acid analyses from urine at diagnosis showed increased urinary intermediary organic acids of the Krebs cycle ([Table 3](#t3-mjhid-9-1-e2017057){ref-type="table"}). This profile with low plasma levels of CAAs and increased urinary excretion, orotic aciduria and hyperammonemia is compatible with a defect in the y+LAT1 sub-unit of the cationic amino-acids transporter encoded by the SLC7A7 gene.

Treatment and outcome
---------------------

Citrulin supplementation to 100 mg/kg/day was prescribed with protein intake limited to 0.8g/kg/day. Liver and spleen enlargement decreased, hypotonia disappeared. The patient has gained 12 kg in two years. He needed repeated platelet and blood cell transfusions during the first month. Hematological disorders have gradually improved with persistent mild anemia not requiring further transfusions ([Table 1](#t1-mjhid-9-1-e2017057){ref-type="table"}). Ammonium, triglycerides, and cholesterol quickly fell to normal levels one month after treatment and are still in average ranges. Fibrinogen value normalized within 5 months. Serum ferritin and LDH fell later after six months giving place to a persistent hyperferritinemia around 2000 ng/ml and permanent increased LDH around 2000 UI/l ([Figure 1](#f1-mjhid-9-1-e2017057){ref-type="fig"}). During follow up, 24 months of treatment, no further authentic HLH occurred.

Discussion
==========

Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammation caused by uncontrolled proliferation of activated lymphocytes and histiocytes.[@b1-mjhid-9-1-e2017057] Often, HLH is an acquired syndrome.[@b5-mjhid-9-1-e2017057] However, HLH can be primitive in children, underlying inherited immune deficiencies.[@b3-mjhid-9-1-e2017057],[@b4-mjhid-9-1-e2017057] An additional HLH cause, the hereditary metabolic diseases and especially HLH related to lysinuric protein intolerance (LPI), is more and more described.[@b6-mjhid-9-1-e2017057]--[@b9-mjhid-9-1-e2017057] The phenotypic heterogeneity of LPI has resulted in various misdiagnoses, of the most frequent is familial lymphohistiocytosis (FLH) given clinical features of HLH which are also often found in LPI.[@b10-mjhid-9-1-e2017057]--[@b12-mjhid-9-1-e2017057]

According to revised haemophagocytic lymphohistiocytosis (HLH) 2004 diagnostic criteria our patient fulfills only four of eight criteria. So, the diagnosis of leaky HLH was kept. Other laboratory findings, which are considered to be of diagnostic value in HLH, were also identified in our patient: hepatic enzyme abnormalities, elevated LDH, elevated VLDL and low HDL. In fact, in these revisited criteria haemophagocytosis in bone marrow aspirate is not constant.[@b1-mjhid-9-1-e2017057],[@b2-mjhid-9-1-e2017057],[@b3-mjhid-9-1-e2017057] Moreover, some patients enrolled in the International Registry of HLH do not fulfill all the diagnostic criteria.[@b13-mjhid-9-1-e2017057] It is currently accepted that hyperferritinemia in LPI is associated with LPI-related HLH even though the other HLH criteria are not prominent.[@b13-mjhid-9-1-e2017057] Therefore, most of the non-metabolic biomarkers of LPI are explained by an underlying chronic or quiescent HLH that can progress to active HLH with fever.[@b14-mjhid-9-1-e2017057] The hepatosplenomegaly observed in LPI reflect HLH rather than the nutritional depletion of CAAs \[[@b15-mjhid-9-1-e2017057]\]. HLH related LPI described in our patient differs from HLH in FLH. In LPI, HLH is chronic and intermittent. The hyperferritinemia and high LDH are usually the only permanent findings.[@b13-mjhid-9-1-e2017057]--[@b15-mjhid-9-1-e2017057] Our patient has never normalized his ferritin and LDH levels. However, in FLH all those abnormalities are reversible and normalized when patients went into remission.[@b1-mjhid-9-1-e2017057],[@b2-mjhid-9-1-e2017057] Then, fever, the most constant feature and typically prolonged in FLH related HLH,[@b1-mjhid-9-1-e2017057] was absent in our patient. It has been described that fever is not a prominent finding in LPI related HLH.[@b7-mjhid-9-1-e2017057] We suggest that patients with suspected HLH, based on the clinical syndrome, should undergo the functional screening that is now a standing point in the diagnosis of HLH and FLH. Based on those findings, the lack of any functional defect could be one more strong argument to evaluate LPI in a child with no fever, growth retardation, and lack of the typical dysfunction of FLH. Distinguishing features between FLH related HLH and LPI related HLH are summarized in [Table 4](#t4-mjhid-9-1-e2017057){ref-type="table"}. The phenotypic heterogeneity of LPI has resulted in various other misdiagnoses reported in the literature such as cases of LPI misdiagnosed as food protein-induced enterocolitis syndrome.[@b16-mjhid-9-1-e2017057] The diagnosis of LPI was also made in a 5-year-old male child followed for 3 years for multiple fractures, idiopathic osteoporosis, and short stature in the absence of typical features of LPI.[@b17-mjhid-9-1-e2017057] These unusual presentations are responsible for diagnosis delay of rare disorders for which early intervention may modify the clinical course.

Our patient, like most of LPI subjects, displayed, other hematological and immunological abnormalities including chronic and intermittent anemia, thrombocytopenia, neutropenia and moderate global lymphopenia. Signs of T-cells dysfunction are usually present whenever investigated in LPI.[@b7-mjhid-9-1-e2017057],[@b14-mjhid-9-1-e2017057],[@b15-mjhid-9-1-e2017057]

The most evocative element of LPI in our patient, calling into question the FLH, was the association of leaky HLH to other features such as failure to thrive, extreme hyperlipidemia, neurological and kidney involvement and the onset of manifestations since food diversification.[@b9-mjhid-9-1-e2017057],[@b11-mjhid-9-1-e2017057],[@b14-mjhid-9-1-e2017057],[@b15-mjhid-9-1-e2017057] Proteinuria and microscopic hematuria should be followed over time since it can develop Fanconi syndrome or end-stage renal disease requiring dialysis.[@b8-mjhid-9-1-e2017057],[@b11-mjhid-9-1-e2017057]

The diagnosis of LPI is based on the presence of, at least, four of the following findings:[@b6-mjhid-9-1-e2017057],[@b11-mjhid-9-1-e2017057] (1) low plasma levels of CAAs; (2) increased urinary excretion of CAAs; (3) orotic aciduria; (4) hyperammonemia generally mild with usual protein intakes, prevented by oral administration of citrulline; and (5) reduced intestinal absorption of CAAs after an oral loading test. The first four criteria were present in our patient. Nutritional imbalance of CAAs does not explain the aberrant inflammatory and immune responses.[@b15-mjhid-9-1-e2017057] The mutation of SLC7A7 gene strongly impairs arginine efflux through system y+L in LPI monocytes and macrophages. It has been suggested that this may have a role in the crosstalk between T lymphocytes and macrophage leading to a defect in lymphocyte cytotoxic activity that prevents the efficient removal of antigens and results in abnormal immune activation of CTLs and macrophages explaining HLH in LPI.[@b18-mjhid-9-1-e2017057],[@b19-mjhid-9-1-e2017057]

There have been rare case reports of HLH secondary to other inborn errors of metabolism. HLH was described in Wolman disease, a severe systemic disease manifesting in the first days of life with vomiting, diarrhea, failure to thrive, hepatosplenomegaly, jaundice, anemia, and thrombocytopenia. A neonatal onset with distinctive markers of the disease such as subcapsular adrenal calcification and the presence of cytoplasmic lipid-laden vacuoles on bone marrow smear indicate an assessment of leukocytic cholesteryl esterase activity on blood leukocytes.[@b20-mjhid-9-1-e2017057],[@b21-mjhid-9-1-e2017057] Biotinidase deficiency should also be considered as a differential diagnosis of patients fulfilling HLH criteria, especially in the presence of ketolactic acidosis and organic aciduria.[@b22-mjhid-9-1-e2017057]

Three cases with organic acidemia who developed HLH during the course of metabolic disorder have been reported. All the patients presented with metabolic acidosis and ketosis and increased histiocytes, lipid-laden macrophages in bone marrow aspirate.[@b23-mjhid-9-1-e2017057] It was reported a case of an infant with early-onset cobalamin C deficiency who presented with HLH with symptoms of feeding difficulty, hypotonia, lethargy, and seizures in the first month of life. Urine organic acid analysis, acylcarnitine profile, and plasma homocysteine could orient to the diagnosis which must be confirmed by specific tests.[@b24-mjhid-9-1-e2017057] HLH has also been described in association with Gaucher disease. Features of Gaucher disease, which are common to HLH, include unexplained fevers and cytopenias, both of which are explainable by the inflammation mediated by macrophages.[@b25-mjhid-9-1-e2017057] In our patient, the cultured fibroblasts enzyme assay revealed normal glucocerebrosidase activity. These cases suggest that a careful metabolic workup should be performed, extending to more advanced tests than organic and amino-acid analyzes when facing to a pediatric patient with HLH especially if clinical features of the patient suggested a metabolic disorder including hypotonia, irritability, or mild developmental delay.

The persistent symptoms mimicking HLH in our patient must be carefully monitored since it can progress to a life-threatening condition. Immunosuppressive drugs should be considered in LPI only when there is a clear threat to life \[[@b9-mjhid-9-1-e2017057], [@b14-mjhid-9-1-e2017057]\] It was reported that combined hyperlipidemia frequently seen in LPI requires a specific treatment with HMG-CoA reductase inhibitors.[@b26-mjhid-9-1-e2017057] However, hyperlipidemia disappeared quickly in our patient. Citrulline treatment does not improve all features in our patient. Large amounts of citrulline increase the intracellular synthesis of arginine and may further stimulate the immune cascade in reticular endothelial cells.[@b15-mjhid-9-1-e2017057] It has been suggested that lysine supplementation could be able to ameliorate the clinical symptoms of LPI that are not corrected by citrulline.[@b27-mjhid-9-1-e2017057]

In a child presenting HLH, a wide range of exams should be performed to rule out an infection, an autoimmune disease or malignancy, since most of these causes are treatable. If primary HLH is suspected, an underlying immune deficiency like FLH, GS, CHS, XLP, should be screened. However, metabolic diseases such as LPI must be kept in mind of specialists as a differential diagnosis of HLH, and a careful metabolic workup should be performed when facing to a pediatric patient with HLH especially if clinical features suggested a metabolic disorder. The lysinuric protein intolerance should be considered in the differential diagnosis of familial lymphohistiocytosis, especially in the absence of fever and the association of atypical clinical and biological features to HLH including hypotonia, irritability, food intolerance, and renal involvement. We suggest that patients with suspected HLH, based on the clinical syndrome, should undergo the functional screening. The lack of any functional defect could be one more strong argument to evaluate LPI in a child with no fever, growth retardation, and lack of the typical dysfunction of FLH. An early diagnosis of LPI can prevent unnecessary intensive immunosuppressive therapy and bone marrow transplantation. LPI related HLH is often chronic and quiescent with permanent hyperferritinemia. However, it must be carefully monitored since it can progress to life-threatening HLH.
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![Outcome of serum ferritin, lactate dehydrogenase (LDH), cholesterol (CH) and triglycerides (TG) before (BT) and after treatment (AT): After citrulline supplementation and low protein diet, Triglycerides and cholesterol levels quickly fell one month after treatment and are steel in normal ranges. However, ferritin and lactate dehydrogenase levels fell later after six months of treatment giving place to a chronic hyperferritinemia stable around 2000ng/ml and permanent increased LDH stable around 2000ui/l.](mjhid-9-1-e2017057f1){#f1-mjhid-9-1-e2017057}

###### 

Hematological findings at admission and during follow up before and after treatment.

  Test               HGB   MCV   MCH   RTC    PLT   WBC     NPg    LY
  ------------------ ----- ----- ----- ------ ----- ------- ------ ------
  Before treatment                                                 
  Admission          5.1   75    24    84.7   48    4.19    1.22   2.12
  Day 30             6.4   75    25    51.8   43    3.25    0.88   1.69
  After treatment                                                  
  1 month            6.6   77    24    44.6   86    13.02   6.03   4.47
  5 months           7.4   88    29    31.4   75    7.16    1.58   4.12
  8 months           7.7   83    26    24.3   57    5.24    1.58   2.78
  12 months          7.9   83    26    31.1   29    2.14    0.73   0.94
  16 months          7.1   92    26    26     91    4.52    1.72   1.95
  19 months          8.9   74    24    30.2   131   5.60    1.90   2.40
  24 months          9.9   91    27    11.7   132   2.99    1.99   1.84

Hemoglobin,

mean corpuscular volume,

mean hemoglobin concentration,

reticulocytes,

platelets,

white blood cells,

neutrophiles,

lymphocytes.

###### 

Immunologic tests at diagnosis.

  Test                     Patient        normal
  ------------------------ -------------- ------------
  CD3(/μl)                 945            2100--6200
  CD4(/μl)                 678            1300--3400
  CD8(/μl)                 487            620--2000
  CD19(/μl)                349            720--2600
  NK (/μl)                 99             180--920
  HLA DR+/CD3+(%)          normal (7%)    \-
  HLA DR+/CD4+(%)          normal (7%)    \-
  HLA DR+/CD8+(%)          normal (6%)    \-
  HLA DR+/Lymphocytes(%)   normal (38%)   \-
  CD25 expression          normal         \-
  Immunoglobilin G (g/l)   7,19           2,69--9,13
  Immunoglobilin M (g/l)   1,38           0,32--1,55
  Immunoglobilin A (g/l)   0,4            0,08--0,54
  Degranulation test       Patient        Temoin
  CD8 (%)                  70             73
  without OKT3             0.75           0.4
  OKT3 0,03mg/l            16.5           11
  OKT3 0,3mg/l             64             57
  OKT3 3mg/l               89             78
  OKT3 30mg/l              96             82

###### 

Results of amino acid analyses from plasma and urine and results of organo-acids from urine.

                             Plasma amino-acids (μmol/l)                             Urinary amino-acids (μmol/mmol creatinin)          
  -------------------------- ------------------------------------------------------- ------------------------------------------- ------ -----------
  Taurine                    46                                                      11--168                                     402    12--159
  Aspartic acid              20                                                      5--33                                       13     3 -- 10
  Hydroxyproline             4                                                       ≤29                                         0      ≤13
  Thréonine                  58                                                      59--135                                     99     15--62
  Serine                     133                                                     87--183                                     285    45--124
  Asparagine                 57                                                      19--71                                      133    ≤32
  Glutamic acid              82                                                      29--119                                     59     ≤11
  Glutamine                  405                                                     362--606                                    389    62--165
  Proline                    128                                                     93--233                                     21     ≤13
  Glycine                    308                                                     160--264                                    810    110--356
  Alanine                    140                                                     174--374                                    196    41--130
  2 aminobutyric acid        8                                                       4--49                                       75     ≤8
  Citrulline                 23                                                      14--42                                      218    ≤7
  Valine                     109                                                     133--293                                    25     7--21
  1/2Cystine                 22                                                      45--113                                     89     10--26
  Methionine                 16                                                      17--29                                      0      7--299
  Isoleucine                 35                                                      31--79                                      7      ≤6
  Leucine                    64                                                      59--151                                     10     3--17
  Tryrosine                  36                                                      39--79                                      68     13--48
  Phenylalanine              68                                                      36--64                                      80     3--31
  Ornithine                  8                                                       25--93                                      392    ≤8
  Histidine                  75                                                      52--104                                     281    87--287
  3-methylhistidine          2                                                       ≤7                                          72     22--57
  Lysine                     66                                                      85--241                                     1408   16--69
  Arginine                   43                                                      34--106                                     602    ≤8
  Total amino-acids          1948                                                    2016--3088                                  6408   700--1465
                                                                                                                                        
                             **Organo-acids from urine (μmol/mmol de créatinine)**                                                      
                                                                                                                                        
                             Patient                                                 Normal                                             
  Lactic acid                152                                                     ≤76                                                
  Glycolic acid              50                                                      ≤92                                                
  3-hydroxypropionic acid    0                                                       ≤4                                                 
  3-hydroxybutyric acid      455                                                     ≤99                                                
  3-hydroxyisovaleric acid   7                                                       ≤35                                                
  Methylmalonic acid         6                                                       ≤9                                                 
  2-Ethylhydracrylic acid    4                                                       ≤12                                                
  Ethylmalonic acid          73                                                      ≤15                                                
  Succiniqc acid             55                                                      ≤97                                                
  Fumaric acid               31                                                      ≤10                                                
  Glutaric acid              6                                                       ≤11                                                
  A.Malic acid               124                                                     ≤11                                                

###### 

Distinguishing features between Familial lymphohistiocytosis (FLH[b](#tfn10-mjhid-9-1-e2017057){ref-type="table-fn"}) related HLH[a](#tfn9-mjhid-9-1-e2017057){ref-type="table-fn"} and lysinuric protein intolerance (LPI[c](#tfn11-mjhid-9-1-e2017057){ref-type="table-fn"}) related HLH[a](#tfn9-mjhid-9-1-e2017057){ref-type="table-fn"}.[@b1-mjhid-9-1-e2017057],[@b2-mjhid-9-1-e2017057],[@b7-mjhid-9-1-e2017057],[@b9-mjhid-9-1-e2017057],[@b13-mjhid-9-1-e2017057]--[@b15-mjhid-9-1-e2017057],[@b18-mjhid-9-1-e2017057],[@b19-mjhid-9-1-e2017057]

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                       FLHb related HLHa                                                                                      LPIc related HLHa
  -------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------
  Mechanism of HLH[a](#tfn9-mjhid-9-1-e2017057){ref-type="table-fn"}   Cytotoxicity/degranulation congenital defect                                                           Impaired arginine efflux in monocytes and macrophages

  Age at onset                                                         Usually early onset (from birth to adulthood)                                                          Typically, after food diversification

  Fever                                                                Nearly constant                                                                                        May be absent

  Hepatosplenomegaly                                                   Nearly constant                                                                                        Nearly constant

  Associated signs                                                     Usually an isolated HLH[a](#tfn9-mjhid-9-1-e2017057){ref-type="table-fn"}                              Multi-organ disease\
                                                                                                                                                                               Failure to thrive\
                                                                                                                                                                               Neurological, hypotonia, developmental disability\
                                                                                                                                                                               Digestive disease, recurrent diarrhea\
                                                                                                                                                                               Renal disease, proteinuria\
                                                                                                                                                                               Pulmonary alveolar proteinosis\
                                                                                                                                                                               Osteoporosis

  Neurological involvement                                             Activation in CSN, (activated lymphocytes in CSF[d](#tfn12-mjhid-9-1-e2017057){ref-type="table-fn"})   Hyperammonemic complications

  Dyslipidimia                                                         High triglycerides                                                                                     Major combined hyperlipidemia, hyper LDL cholesterol

  Hyperferritinemia, anemia, and thrombocytopenia                      During HLH episode                                                                                     Chronic

  Bone marrow hemophagocytosis                                         Phagocytosis of erythrocytes and platelets by histiocytes                                              Participation of neutrophil precursors and exclusive phagocytosis of pyknotic polymorphonuclear leukocytes and acidophilic erythroblast nuclei.

  HLH severity                                                         Usually complete and severe HLH[a](#tfn9-mjhid-9-1-e2017057){ref-type="table-fn"}                      Usually leaky HLH[a](#tfn9-mjhid-9-1-e2017057){ref-type="table-fn"}^,^

  Immunologic abnormalities                                            Perforin defect and/or negative degranulation test                                                     No functional defect, possible lymphopenia, hypogammaglobulinemia

  Immunosuppressive treatment                                          Mandatory, no spontaneous regression                                                                   Indicated only when life-threatening HLH despite dietary treatment and citrulline

  Outcome                                                              Free interval between two HLH[a](#tfn9-mjhid-9-1-e2017057){ref-type="table-fn"} episodes               HLH features are quiescent and chronic\
                                                                                                                                                                              Hyperferritinemia and elevated serum LDH are permanent findings

  Prevention of relapses                                               Mandatory up to HSCT                                                                                   Not indicated
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Hemophagocytic lymphohistiocytosis,

familial lymphohistiocytosis,

lysinuric protein intolerance,

Cerebro-spinal fluid,

Hematopoietic stem cell transplantation.
